Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HBM HoldingsFRA:6XY 64 Days Inventory is 197.14 as of Dec. 2025, which is 4% above its 10-year median of 189.96. GuruFocus rates FRA:6XY with a GF Score™ of 64/100 and a GF Value™ of €0.74 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 638 Biotechnology companies, HBM Holdings ranks better than 58.31% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). HBM Holdings's Average Total Inventories for the
six
months ended in Dec. 2025 was €3.6 Mil. HBM Holdings's Cost of Goods Sold for the
six
months ended in Dec. 2025 was €3.3 Mil.
Hence, HBM Holdings's Days Inventory for the
six
months ended in Dec. 2025 was 197.14.
The historical rank and industry rank for HBM Holdings's Days Inventory or its related term are showing as below:
FRA:6XY'
s Days Inventory Range Over the Past 10 Years
Min: 148.83 Med: 189.96 Max: 2928.65
Current: 148.83
During the past 8 years, HBM Holdings's highest Days Inventory was 2928.65. The lowest was 148.83. And the median was 189.96.
FRA:6XY's Days Inventory is ranked better than 58.31% of 638
companies
in the Biotechnology industry
Industry Median: 182.94
vs FRA:6XY: 148.83
HBM Holdings's Days Inventory
increased
from Dec. 2024 (82.19) to Dec. 2025 (197.14).
It might indicate that HBM Holdings's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
HBM Holdings's Inventory Turnover for the
six
months ended in Dec. 2025 was 0.93.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
HBM Holdings's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.07.
HBM Holdings (FRA:6XY) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
HBM Holdings's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
HBM Holdings's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
HBM Holdings Days Inventory Related Terms
HBM Holdings Days Inventory Historical Data
* Premium members only.
The historical data trend for HBM Holdings's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6XY vs VRTX, REGN, RVMD: Days Inventory Comparison
For the Biotechnology subindustry, HBM Holdings's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HBM Holdings Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HBM Holdings's Days Inventory distribution charts can be found below:
* The bar in red indicates where HBM Holdings's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBM Holdings (FRA:6XY) has a Days Inventory of 197.14 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on HBM Holdings and its competitors. This is near median its historical median of 189.96. Over the past decade, HBM Holdings' Days Inventory has ranged from 148.83 to 2,928.65. According to the industry distribution chart, HBM Holdings ranks #266 out of 638 companies in the Biotechnology industry, placing it in the top 41.7%.
Is HBM Holdings' Days Inventory too high?
HBM Holdings' current Days Inventory of 197.14 is near median its 10-year median of 189.96. Over the past 10 years, this metric has ranged from a low of 148.83 to a high of 2,928.65. The Biotechnology industry median Days Inventory is 182.94. HBM Holdings' value of 197.14 is 7.8% above this industry median. Based on the distribution chart, HBM Holdings ranks #266 out of 638 companies in the Biotechnology industry, which is above the industry midpoint. Overall, HBM Holdings has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HBM Holdings' Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HBM Holdings ranks #266 out of 638 companies for Days Inventory. This puts HBM Holdings in the upper half of its industry. The industry median Days Inventory is 182.94. HBM Holdings' value of 197.14 is 7.8% above this benchmark. Historically, HBM Holdings' own Days Inventory has ranged from 148.83 to 2,928.65 over the past decade. While the company's 10-year median is 189.96 vs. the industry median of 182.94, HBM Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 182.94, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HBM Holdings's current Days Inventory of 197.14 is 7.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on HBM Holdings and its competitors. For the Biotechnology industry, the median Days Inventory is 182.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HBM Holdings's current Days Inventory is 197.14, which is near median its own 10-year median of 189.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HBM Holdings stock overvalued right now?
Based on GuruFocus' analysis, HBM Holdings (FRA:6XY) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.74, compared to a current price of €1.33 — trading 79.7% above its estimated fair value. The current Days Inventory is 197.14, which is near median its 10-year median of 189.96 and 7.8% above the Biotechnology industry median of 182.94. HBM Holdings' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For HBM Holdings (FRA:6XY), the current Days Inventory is 197.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HBM Holdings (FRA:6XY) Overvalued in 2026?
Based on GuruFocus' analysis, HBM Holdings stock appears to be overvalued.
The current stock price of €1.33 is trading 79.7% above its estimated GF Value™ of €0.74.
GuruFocus considers HBM Holdings to be Significantly Overvalued.
Key valuation signals for FRA:6XY:
Days Inventory: 197.14 (near median its 10-year median of 189.96)
GF Value™: €0.74 vs. price of €1.33 (79.7% above fair value)
Industry Position: 7.8% above the Biotechnology median (#266 of 638)
No single metric tells the full story. See the FRA:6XY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the Europe.
64GF Score
Get the complete analysis for FRA:6XY
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6XY has been successfully added to your 
